儿童急性髓系白血病的治疗进展  

The therapeutic improvement of pediatric acute myeloid leukemia

作　　者：孙维梅[1] 李建厂[1] 

机构地区：[1]滨州医学院附属医院儿童血液科,256603

出　　处：《国际儿科学杂志》2015年第2期159-162,共4页International Journal of Pediatrics

摘　　要：急性髓系白血病（acute myeloid leukemia,AML）是一组异质性疾病,约占15岁以下儿童所有确诊肿瘤的15％～ 20％,在过去的几十年里,儿童AML的长期预后取得了巨大的进展.基于AML临床和生物学特征的更加完善的危险度分层,抗白血病药物更加有效的应用以及在支持治疗方面的进展使得儿童AML治愈的可能性达到了60％左右.该文就儿童AML在化疗方案和化疗药物方面的新进展作一综述.Acute myeloid leukemia（AML） is a heterogeneous kind of disease,which is accounting for 15% ～ 20% of all tumors diagnosed in children under 15 years of age.In the past few decades,remarkable improvements have been yielded in long-term outcomes for children with AML.A better risk-group stratification of disease,which is based on clinical and biological features,a more effective use of anti-leukemia agents and enormous improvements in supportive care have increased the rate of cure by approximately 60%.This paper review the new improvements in the chemotherapeutic regimens and drugs.

关 键 词：急性髓系白血病 化疗方案 靶向治疗 儿童 

分 类 号：R733.71[医药卫生—肿瘤]